Tech Leaders’ Money in Biotech Reached Public Stocks First Through Acquisitions and Narratives: A Map of 94 Companies and a Review of U.S. and Korean Listed Companies

Sat, 10 Oct 2026 22:30:00 +0900

Altman, Zuckerberg, Bezos, Gates, Thiel, and Khosla have invested in 94 companies across biotech, longevity, and medical technology in the list reviewed for this analysis. Only 10 of them currently trade under their own tickers. The rest are private, have been absorbed by other companies, or have disappeared.

For investors looking at listed stocks, one question remains: How does private-company funding reach the results of listed companies, and how is the stock market valuing that today? Aging and brain interfaces attracted the most money, yet have virtually no listed proxies. Where the money has reached listed companies, acquisition prices and revenue multiples have moved before operating results. Here is the conclusion first.

Money invested in private biotech reached listed stocks first through acquisitions and narratives. It has not yet been confirmed in operating results. Third-quarter results and FDA decisions are the first test of whether those narratives turn into revenue and approval language. When interest rates are rising, cash burn determines the downside for companies that fail this test.

The areas that attracted the most money have the fewest listed proxies. Of the 94 companies, exposure through listed stocks can be confirmed for only 10. We found no listed company generating revenue from brain interfaces. Clinical trials at listed companies focused on aging do not use aging itself as an indication.
The clearest route for money to reach listed markets is through acquisitions. IQVIA counted 42 biopharma acquisitions in the first half of 2026, worth $130 billion. Ten of the 13 companies Lilly has acquired this year were private.
In U.S.-listed stocks, narratives have shown up in multiples. Revenue at three diagnostics companies grew 26% to 44%, and their multiples range from 19x to 33x. Large-cap tools companies grew revenue 5% to 10% and trade at 6x to 9.5x. Revenue at AI drug-discovery platforms fell 38% to 76%, but clinical events drove divergent share-price performance.
Interest rates have changed the market baseline. XBI is up 26.1% this year but down 6.4% over the past three months. The 10-year Treasury yield rose from 4.18% at the start of the year to 5.24%. Late-stage assets trade at 1x to 3x cash, while narrative-driven stocks trade at 4x to 13x.
In Korea, Samsung Biologics and ST Pharm are the only companies with overseas contracts confirmed through disclosures and positive first-half results. Cell and lab-automation companies with overseas evidence reported first-half revenue in the KRW 500 million to KRW 4.6 billion range, and all posted losses.

The analysis date for private investment events is Oct 9, 2026. U.S. share prices are closing prices from Oct 9. Results for U.S.-listed companies are based on their second-quarter 2026 reports. Korean disclosures and news were checked on Oct 10. Korean markets were closed on Hangul Day, Oct 9. Price returns exclude dividends. Secondary sources and our own calculations are identified as such in the main text.

94 Companies Focus on Drug Discovery and Cell Therapy, but Each Leader Backs Different Themes

The list of 94 includes biotech, longevity, and medical technology companies funded or founded by tech leaders, along with historical ventures, with no duplicates. Of these, 90 have an investment or founding connection to an individual, an affiliated fund, or a foundation. That does not mean all 90 were direct personal investments, or that the list contains only private companies that are still active.

The other four are not counted as personal investments. Spring Discovery is linked to Altman only in a supplementary investment database, so its attribution needs further verification. Calico, founded by Google, was a corporate venture and is not counted as a personal investment by Larry Page. Ambience Healthcare and Thrive AI Health, which the OpenAI Startup Fund invested in or co-launched, are included only as comparisons for affiliated capital.¹²

Personal investments, affiliated investment firms and funds, foundation equity investments, corporate investments, and donations are different kinds of money. The long-term preferences of wealthy individuals, the return targets of venture funds with fixed terms, and the public-benefit conditions of foundations may differ. For this reason, SIF, the Gates Foundation’s equity investment vehicle, is counted separately from Bill Gates personally. Investments by the OpenAI Startup Fund are also not treated as Altman’s personal investments.³

I did not aggregate or calculate total investment amounts, company valuations, or investment success rates. Individual contributions are mostly undisclosed, and publicly reported cases are subject to selection bias. Unless stated otherwise, the amounts in this article refer to the total size of a company’s funding round.

I verified 81 connections using event-specific primary sources from companies, investors, or disclosures, or official portfolio lists. Another 12 rely in whole or in part on media reporting, and one was verified only in a supplementary database. These evidence grades show how firmly an investment connection was verified. They are not scores for technology, clinical, or financial quality. An appearance on an official list does not prove current ownership, the investment date, or the amount invested.

Capital Is Concentrated in Aging and Brain Interfaces, but Effects in People Are Still Years Away

By theme, AI and data-driven drug discovery has the most companies, with 13, followed by cell, gene, and organ therapies, with 12. The map asks whether the themes attracting capital are also those that can be validated through customer cash flows. The horizontal axis shows how close a theme is to validation through external customers or contract revenue. The vertical axis shows the intensity of capital inflows, based on funding rounds disclosed in 2025–2026.

Circle size represents the number of companies in each theme. Each company is assigned to only one theme. The placement of the circles is this analysis’s assessment, based on disclosed funding rounds and research priorities. It is not a measured value.

In the upper right are aging and reprogramming, with 9 companies, and brain interfaces, with 7. These themes attract large rounds, but confirming effects in people is still years away. Investors should first check whether current prices already assume success. They should also assess the cash available to fund the next validation and the reserves for redesign after a failure.

Medical AI and workflow, medical devices and surgery, and prevention and consumer health are in the upper left. Capital is flowing into these areas, and customer validation is also possible. Cell and experiment automation and measurement are in the lower left. Funding rounds are quieter, but these themes can be validated through yield, costs, and recurring revenue. The left side of the map is where additional research time is most likely to improve the assessment.

Seven vaccine and infectious disease companies involve Gates Foundation equity investments that may carry public-benefit conditions. The nine companies focused on healthcare access and coverage mainly provide insurance and appointment software. I include these themes only for comparison because they require different biotech diligence standards.

Khosla Is Spread Across Many Themes, While Musk Has Only Neuralink

The numbers in each cell of the investor distribution chart count investment connections. They do not represent investment amounts or ownership stakes. When two leaders are connected to one company, it is counted in both rows, so the sum of the rows exceeds 94. The chart asks whether leaders concentrate on the same themes or invest across different ones.

Khosla Ventures has the broadest reach, with 40 companies. Its investments are concentrated in medical AI and workflow, healthcare access and coverage, and cell, gene, and organ therapies. The 40 consist of 37 additional companies from its official portfolio, plus Somite AI, Synchron, and Relation Therapeutics, which had already been identified alongside other leaders.⁴

Bezos Expeditions spans 10 companies, including ones focused on diagnostics, devices, drug discovery, and aging. Altman’s row has 11 companies and extends beyond aging into drug development, cell therapy, diagnostics, reproductive health, and the brain. The row also shows comparison connections to OpenAI, but these are not counted as personal investments.⁵

Musk’s row contains only Neuralink. Zuckerberg and Chan are involved in cell data, preventive care, and healthcare access through personal investments and Chan Zuckerberg Initiative (CZI) venture investments. The Gates Foundation SIF row appears only in the vaccine and infectious disease cell, showing that despite the shared Gates name, it differs in nature from personal investments.⁶

Capital Events Were Dense Over the Past 16 Months, While Human-Impact Events Were Rare

From June 2025 through October 2026, events involving companies connected to tech leaders are plotted across two tracks. The top track shows disclosed financing and corporate investments. The bottom track shows clinical, trial, regulatory, and going-concern events. The figure asks whether evidence in humans accumulated as quickly as the money came in.

The top track shows eight company funding rounds exceeding $100 million. Neko Health’s Series C and Neuralink’s Series E were the largest. Rounds by NewLimit, HistoSonics, Synchron, Profluent, LifeMine Therapeutics, and Ambience, a comparable, also exceeded this threshold.⁷⁸

During the same period, two events involving human results came from GRAIL. In May 2026, the NHS-Galleri trial did not meet its primary endpoint of reducing the combined incidence of stage 3 and 4 cancers, while some secondary outcomes improved. On September 23, an FDA advisory committee issued a positive opinion, but this was not final approval.⁹¹⁰

Retro Biosciences’ RTR242 entered Phase 1 in May 2026. Since Phase 1 marks the start of safety testing, it was not counted as a results event. NewLimit’s first human trial is planned for 2027, outside the figure’s time frame. No aging company disclosed improved human function during this period.¹¹

On September 26, 2025, the dissolution of Unity Biotechnology, which had targeted senescent cells, took effect. Bezos Expeditions had reportedly invested in the company.¹²¹³

In the same year, 23andMe went bankrupt, and the nonprofit public benefit corporation TTAM Research Institute acquired its assets. Sergey Brin had invested his personal funds in the company. High-profile investors and long-term capital did not prevent individual companies from failing.¹⁴¹⁵

On October 7, 2026, Reuters reported that the U.S. government and Google would participate in an $1.8 billion AI biology initiative at Biohub, which is backed by Zuckerberg. Biohub is a nonprofit public data initiative, so it is shown separately from company funding rounds. CZI’s equity investment is also kept separate from Biohub’s research support.¹⁶

As AI makes it easier to generate hypotheses, the relative value of experimental data that can determine which hypotheses are correct, and of production capacity, increases. As public data grows, startups that train on that data become less differentiated. Companies with proprietary data that includes failed experiments, and that use it to improve subsequent experiments, gain an advantage. This is an inference in this analysis drawn from public events, not a fact verified through company-specific results.

Gordian Biotechnology’s 2026 collaboration with Pfizer to identify obesity targets is a relevant example of this trend. Gordian generates intervention and response data in living organisms, and is connected to an investment firm associated with Jeff Dean. The financial terms of the collaboration could not be confirmed in this research.¹⁷

Aging Attracts the Most Capital, but No One Has Reached the Human Functional Outcomes Stage

A reduction in epigenetic age, changes in cell function, effects in animals, human safety, improved human function, and lower disease incidence and mortality are separate validation stages. Counting success at an earlier stage as success at a later one inflates valuations. The ladder figure answers how far aging and reprogramming companies have progressed based on public announcements.

The most advanced company, Retro, is at the human safety (Phase 1) stage. Altman’s initial investment of $180 million was reported, and a pre-money valuation of $1.8 billion was disclosed at the first close of a follow-on round in May 2026. RTR242 entering Phase 1 does not prove reprogramming or healthspan extension.¹⁸¹¹

NewLimit, co-founded by Brian Armstrong, raised $435 million in a 2026 Series C, but its first human trial is planned for 2027. Altos Labs announced a $3 billion commitment at its launch in 2022, but this research did not confirm any publicly disclosed clinical trials. The figure places NewLimit at the animal effects stage and Altos at the cell function change stage.¹⁹²⁰

Unity reached human trials but dissolved in September 2025. This research found no one at the stages of improved human function or reduced disease incidence and mortality. Loyal, which works with dogs, is not placed on the human ladder.

The judgment that aging research is wrong differs from the judgment that current prices already assume success. Investors may want to look first at companies that can explain which function they aim to improve in which patients, rather than companies that first promise people a longer life.

The specific disease programs on the lower row of the ladder can define clear comparables and metrics. Aspen Neuroscience aims to replace Parkinson’s disease neurons using stem cells made from a patient’s own cells (autologous iPSCs), while Lifemine’s LIFE-001 targets organ transplant rejection. Neuralink and Synchron’s efforts to restore function in people with severe paralysis, and NewLimit’s liver program, belong in the same group.²¹

Brain interfaces use different patient, procedure, and insurance pathways, even when they involve the same brain technology

Neuralink announced $650 million in Series E funding on June 2, 2025. This was a company-wide round, and its main development goal is restoring function for people with severe paralysis. This does not support reading Musk as investing broadly in rejuvenation or longevity drugs, nor does it prove that he has made no other investments. Science Corp, which appears on Khosla’s list, was also not classified as a Musk investment based only on its founder’s background.⁸

The figure places brain technology companies with tech-leader involvement by degree of invasiveness. Differences in invasiveness also mean differences in target patients, safety standards, the number of hospitals able to perform procedures, and insurance coverage pathways.

At the far left, Neuralink inserts a device directly into the brain, while Synchron inserts one through a blood vessel. Synchron, backed by Bezos Expeditions, Gates Frontier, and Khosla Ventures, raised $200 million in a 2025 Series D. Vascular access avoids opening the skull but remains an invasive procedure.²²

In the center, Merge Labs is a research company co-founded by Altman and backed by OpenAI. It was officially announced on January 15, 2026. Its approach has not been disclosed, so the figure places it in the center. Altman’s personal investment amount has also not been disclosed. On the right are Starfish Neuroscience, co-founded by Gabe Newell, and Kernel, a non-invasive brain measurement company founded by Bryan Johnson.²³

Evaluation in this field focuses on long-term signal stability, the safety of insertion and removal, and the functions patients actually recover, rather than channel count or demonstration videos. The number of hospitals able to perform procedures and the likelihood of insurance coverage determine the revenue pathway. Restoring medical function and enhancing the abilities of healthy people are not counted as the same market.

Widely reported figures often describe neither capital raised nor personal investment nor clinical results

Retro’s $1.8 billion figure is its pre-money valuation, not the amount raised. Taking the largest number in a report at face value can lead investors to misread cash runway and the stage of validation. The table below ranks the figures corrected in this research by how easily investors could misread them.

Figure shown	Company and date	What it actually means	Misreading it could lead to
$1.8 billion	Retro, 2026-05-22	Pre-money valuation. Amount raised undisclosed; first close of a follow-on round	Treating the valuation as capital raised and overstating cash runway
$3 billion	Altos Labs, launched in 2022	Total committed capital. Not Bezos’s personal investment	Confusing commitments with deployment, or an individual with the whole fund, and misattributing the amount
$263 million	LifeMine, announced in 2026-08	The combined total of a $75 million Series D and a $188 million Series E	Treating them as one round and missing the differences in participation timing and price
75%	Neko Health, 2026-07	The share of customers who booked and prepaid for another test after their first test	Mistaking it for the actual return rate the following year or long-term retention
Positive advisory committee view	GRAIL, 2026-09-23	An FDA advisory committee assessment, not final approval	Reading only the favorable development and omitting the missed primary endpoint earlier that year
37	Khosla Ventures portfolio list	Investment links confirmed in the official portfolio	Mistaking these for Khosla’s personal investments, current holdings, or clinical validation
$650 million	Neuralink, 2025-06-02	A company-wide funding round. Its goal is to restore function for people with severe paralysis	Stretching it into evidence for a rejuvenation or longevity drug portfolio

LifeMine’s Series D closed in Q4 2025, and its Series E closed in July 2026. Bezos- and Gates-related investment firms joined in the E round. Even when investors back the same company, different participation dates and prices make them different bets.²¹

Neko Health is a screening company that combines its own sensors, blood tests, and physician consultations. It is not a whole-body MRI company. Its 75% figure may signal strong demand, but whether the service is medically useful requires separate validation. For GRAIL, the analysis should also follow the burden of tests and procedures after a finding, why insurers would pay, and whether that translates into company profits.⁷

What changes for investors is the order in which they read the figures. First determine whether an amount refers to capital raised, valuation, or commitments. For a percentage, check whether it means a booking or an actual return visit. For a regulatory event, check whether it is an advisory opinion or an approval.

Recovery and Clinical Success Are Different Questions

The outcomes of companies backed by famous investors differ across financing, investor exits, clinical or product success, and patient benefit. The table separates cases that are easy to group under the same label of “success” or “failure.”

Case (associated investor)	Outcome	What is confirmed	What to assess separately
Juno Therapeutics (Bezos Expeditions)	Celgene acquisition completed in 2018-03	Sale of the company created an exit path	Actual returns for individual investors
Kymab (Gates Foundation Strategic Investment Fund (SIF))	Acquired by Sanofi in 2021	Sale of the company	Differences between the foundation’s public-benefit conditions and commercial investors’ objectives
Affinivax (Gates Foundation Strategic Investment Fund (SIF))	Acquired by GSK in 2022	Sale of the company	Progress of programs after the acquisition, as confirmed in the acquirer’s disclosures
Stemcentrx (Founders Fund)	Rova-T development discontinued in 2019 after AbbVie acquisition	VC exit through the acquisition; lead asset discontinued	VC exit and the acquirer’s business performance are separate
Unity Biotechnology (Bezos Expeditions, according to reports)	Dissolution effective 2025-09-26	Financing took place	Long-term capital could not prevent an individual company’s failure
23andMe (personal funds from Brin)	After its 2025 bankruptcy, TTAM acquired its assets	Data assets remain	The scientific value of the data and the value for existing shareholders are separate

Juno Therapeutics was acquired by Celgene in March 2018, but the actual exit returns for Bezos Expeditions have not been confirmed.²⁴

Kymab, in which the Gates Foundation Strategic Investment Fund (SIF) held an equity stake, was acquired by Sanofi in 2021. Affinivax was acquired by GSK in 2022. The foundation’s public-benefit conditions may differ from commercial investors’ objectives.²⁵²⁶

Stemcentrx, backed by Peter Thiel’s Founders Fund, was sold to AbbVie. Development of its lead asset, Rova-T, was discontinued in 2019. VC exit and the acquirer’s clinical and business performance are different questions.²⁷²⁸

All cases involved successful financing, while only the acquisition cases involved exits. Clinical or product success and patient benefit must mostly be assessed separately. This sample was not used to calculate the success rate of biotech investing or the investment ability of famous people. An acquisition announcement means only that an exit path emerged. It is not evidence that the acquired asset will succeed clinically.

Venture investors can investigate experimental automation and proprietary data first

Somite, Cellino, and Vivodyne are companies that connect AI models to cell production and experiments. The reason to look at the left side of the map first is that as hypothesis generation becomes easier, the value of judgment data and production capacity rises. The order below is not a ranking of investment attractiveness. It is the order in which research time is likely to improve judgment the most.

We did not obtain valuations, shareholder registers, cash balances, or original contracts. Therefore, this order is not an investment recommendation for any individual company.

Order	Type	Representative companies	Evidence to check first
Priority	Experiment and cell automation	Somite, Cellino, Vivodyne, Opentrons	Reproducibility verified by external customers, batch yield and cost, recurring revenue
Priority	Proprietary experimental data	Gordian, Relation, insitro	Commercial usage rights, causal links between interventions and disease responses, predictive power on external data
Priority	Molecular design	Profluent, Atomic AI	Experimental success rate versus the model alone, delivery, manufacturing, and safety, contract cash
Priority	Clinical workflows and diagnostics	Abridge, Rad AI, Ambience, Karius	Simultaneous improvement in time, errors, medical costs, and paid renewals
Conditional	Medical devices	HistoSonics, Synchron	Function and safety by indication, usage after installation, procedure and reimbursement revenue
Conditional	Preventive care	Neko, Grail, Viome	Actual long-term retention, follow-up costs after false positives, benefit versus control groups
Long-term watch	Aging and organ preservation	Retro, NewLimit, Altos, Until, eGenesis	Improvement in human function, long-term safety, funding through the next validation milestone

Compare cell and experiment automation on the same basis: target-cell production rate, batch failure rate, manufacturing time, quality-testing cost, freezing and thawing losses, and cost per dose. Do not evaluate automation built for one customer as a repeatable sales platform.

Break down “platform” revenue into software subscriptions, contract research, co-development, upfront payments, conditional milestones, and royalties. Cash already received, cash that may be received, and the maximum amount payable only upon ultimate success carry different risks.

Companies in the long-term watch category also require an accurate reading of their business. NewLimit is developing therapies that alter the epigenetic state of cells. Until Labs is developing cryopreservation and rewarming technology for transplant organs. Reading Until as a business for freezing and reviving entire people would miss its actual development task.²⁹

The evidence that would change the assessment is not additional participation by famous investors. The assessment should change when independent effects in humans, repeatable production, actual contract cash, and funding durability are demonstrated. Applying the same criteria to public stocks reveals how money concentrated in private companies reaches listed companies.

Private Money Reached Listed Stocks First Through Acquisitions, and the Path Narrows in Hotter Themes

Of the 94 companies on the list, 10 currently trade under their own tickers. The rest are private, have been absorbed by other companies, or have disappeared. For listed-equity investors, the remaining question is how this money reaches listed-company results.

The Clearest Path Is Through Acquisitions and Licensing by Large Companies

The events completed or announced between October 2025 and October 2026 trace the paths shown in the figure. Private themes reach listed-company results through acquisitions and licensing, supply chains, competition, listings, and regulation and coverage.

Even within the same theme, the numbers investors need to check depend on the path. For acquisitions, they should look at the asset’s share of the large company’s revenue. For listings, they should look at the new ticker’s cash burn.

Acquisitions and licensing provide the clearest evidence that private-company value has transferred to a listed company. Abbott completed its acquisition of Exact Sciences in March 2026.³⁰ Lilly completed its acquisition of AtaiBeckley in September.³¹ Along this path, the value created at the private-company stage is absorbed into the large company’s results, and any single asset accounts for only a small share.

Along the supply-chain path, equipment and reagents used by private companies are recorded as revenue by listed suppliers. Spending by lab automation and cell-data companies flows to equipment and reagent companies such as Thermo Fisher, Danaher, and Tecan. In consumer testing, Quest Diagnostics runs blood tests for the WHOOP app.³² However, this revenue is diluted within the larger company, and Quest does not disclose the share of revenue from consumer channels.

Along the competition path, established players offer the same functions directly. Private capital has flowed to companies such as Abridge, which uses AI to transcribe clinical conversations. But electronic health record company Epic launched its own AI documentation feature in February 2026.³³ Microsoft said that more than 100,000 clinicians use Dragon Copilot daily.³⁴

The listing path first opened with comparable companies. Hinge Health listed in the United States in May 2025.³⁵ Protein-design AI company Generate Biomedicines listed on Nasdaq in February 2026.³⁶ This created the closest listed comparable for private protein-design AI companies.

Freenome is the only company on the list of 94 to have listed recently. It listed on Nasdaq on July 20, 2026, through a SPAC merger.³⁷ One week after listing, its blood test for colorectal cancer received FDA approval, but Abbott has exclusive rights to sell it in the United States.³⁸

The regulation and coverage path is still pending, so it is shown with a dashed line in the figure. The Medicare MCED law, signed in February 2026, opens the way to coverage starting in 2028 for tests that receive FDA approval.³⁹ GRAIL’s Galleri received more favorable than unfavorable votes at an FDA advisory committee meeting on September 23, but the date of a final decision has not been made public.⁴⁰

There is also a case where coverage has taken effect. Guardant Health’s Shield blood test for colorectal cancer was added to the American Cancer Society’s screening guidelines in May 2026. In July, UnitedHealth announced that it would cover the test.⁴¹

Whichever path a company takes, converting a private-market valuation into revenue for a listed company takes time. Takeda acquired Nimbus’s TYK2 inhibitor in 2023, and the drug entered priority review for an FDA new drug application only in September 2026.⁴² The PDUFA target action date is in the first quarter of 2027. This is why news of a private funding round is difficult to read directly as a signal of listed-company results.

For Listed Companies Backed by Famous Investors, First Check Whether the Ticker Remains

Of the 94 companies on the list, 15 have traded as listed stocks in recent years. Will these companies still have tickers in October 2026?

Nine remain listed, and Freenome is the only new listing. These are the 10 companies for which direct exposure through listed stocks can be confirmed.

Among the companies that lost their tickers, CureVac and AtaiBeckley disappeared through acquisitions. Trading in CureVac halted in January 2026 after BioNTech’s exchange tender offer ended.⁴³ AtaiBeckley is the renamed former ATAI, and Lilly’s acquisition closed in September.³¹

The others disappeared after failing. Vicarious Surgical, a small surgical robotics company, liquidated after trading was suspended on the New York Stock Exchange in March 2026.⁴⁴ Unity Biotechnology, which focused on treatments for aging, dissolved after being delisted in August 2025.⁴⁵ 23andMe’s assets were sold to TTAM Research Institute, a nonprofit public-benefit corporation, after it filed for bankruptcy.⁴⁶

These five companies lost their listed status between March 2025 and September 2026. The names of famous investors and long-term capital did not prevent individual companies from failing. When reviewing a listed company associated with a tech leader, first check whether its ticker still exists.

The private companies shown in the bottom row of the figure, such as HistoSonics and Neuralink, simply had no S-1 registration statement appear in the search. This is a search-based result, so it is not evidence that they have no plans to list.

The Bigger the Money Flowing Into a Theme, the Fewer Listed Proxies There Are

We found no listed company that generates revenue solely from brain-computer interfaces (BCIs). That means there is no listed proxy: no listed company earning revenue from the same area as the private theme. Among listed companies, ONWARD Medical, traded on the Belgian exchange, is the only one conducting human BCI trials, and its BCI revenue is zero.⁴⁷

Funding on the private side is substantial. Synchron raised $200 million in a Series D round in November 2025.⁴⁸ We found no BCI company among the 94 on the list, including Neuralink and Synchron, that had announced a listing or SPAC merger.

The listed-company side is also empty for the aging theme. The drug BioAge Labs is testing is an NLRP3 inhibitor targeting cardiovascular inflammation, despite the company’s focus on aging biology.⁴⁹ Longeveron, which started with a focus on treating frailty, failed to meet its primary endpoint in a pediatric heart disease trial on September 16, 2026, and began reviewing strategic alternatives.⁵⁰

Xenotransplantation, the transfer of organs from other species into humans, has listed and private companies at the same starting line. United Therapeutics’ xenotransplantation kidney, UKidney, directly competes with the kidney developed by private company eGenesis. Both companies have zero xenotransplantation revenue, and most of United Therapeutics’ revenue comes from pulmonary arterial hypertension drugs.⁵¹

Consumer preventive screening shows the same pattern. Neko Health raised $700 million in July 2026, but we found no listed company offering the same kind of full-body scan.⁵² Smart-ring company Oura delayed its schedule shortly before its listing after making its registration statement public in September. The delay was reported by a single outlet, and we could not confirm it against a company source.⁵³

For the private value in these themes to flow into listed markets, an acquisition or listing would need to follow initial human results. This is an inference from this analysis. The judgment about which themes have attracted large amounts of money also relies on disclosed funding-round amounts; it is not based on a sum of total investment.

Comparables Are Common in Diagnostics, Coverage, and Lab Equipment, but Absent in Brain and Aging Themes

Which listed companies can serve as comparables for each theme? The table below groups listed companies by theme when they share the same revenue source, and also notes why the connection may be weak.

Theme	Comparables (tickers)	Reason for connection	Caveat
Cell, lab automation, and measurement	Tecan (TECN)·Illumina (ILMN)·10x (TXG)·Twist (TWST)·Thermo Fisher (TMO)·Danaher (DHR)	Equipment, reagents, and DNA inputs used by private lab companies show up as revenue	Theme revenue is diluted at larger companies. A small company in single-molecule protein analysis has pushed its launch to 2027
Molecular design AI	Generate (GENB)·Schrödinger (SDGR)·Absci (ABSI)	Generate’s Phase 3 trial is the first clinical test of a design model. Schrödinger sells software	Absci has no efficacy data and relies on equity raises
AI and data-driven drug discovery	Recursion (RXRX)·AbCellera (ABCL)·Insilico (3696.HK)·Tempus (TEM)	Cash comes in through licenses with large pharmaceutical companies	Most of the total contract value is conditional. No listed company has reached the approval stage
Diagnostics and screening	Grail (GRAL)·Guardant (GH)·Freenome (FRNM)·Natera (NTRA)·Abbott (ABT)	Screening guidelines, insurer coverage, and Medicare law shape the revenue route	Grail’s FDA decision date is undisclosed. Freenome has said it needs additional financing
Medical AI and workflows	Tempus·Doximity (DOCS)·Waystar (WAY)	Data licensing and the acquisition of AI for documentation and coding (Waystar)	No pure-play proxy. Epic and Microsoft are competing routes
Healthcare access and coverage	Oscar (OSCR)·Hinge Health (HNGE)·Omada (OMDA)	This is a theme with an actual listed route. Hinge directly competes with Sword Health	Oscar is exposed to enhanced subsidy expiration and CMS estimates of subscriber declines under 2027 rules
Cell, gene, and organ therapies	Lonza (LONN)·MaxCyte (MXCT)·United Therapeutics (UTHR)·Intellia (NTLA)	Manufacturing supply chain and direct competition in xenotransplantation kidneys	Both sides have zero revenue from xenotransplantation. Intellia is a comparator for regulatory precedents
Medical devices, prevention, and vaccines	Intuitive (ISRG)·Quest (DGX)·Hims (HIMS)·BioNTech (BNTX)·Vir (VIR)·Moderna (MRNA)	Intuitive is an established leader in surgical robotics. Quest is part of the consumer testing supply chain. Vir receives upfront license payments	Quest’s consumer share is undisclosed. Foundation ownership may carry public-benefit conditions
Brain interfaces and aging	ONWARD (ONWD)·BioAge (BIOA)·Longeveron (LGVN)	These are listed companies that claim the same theme, but the connections are weak	BCI revenue is zero, and there are no products for aging indications. In effect, there is no proxy

The table does not include share prices or market capitalizations. Even among companies in the same row, theme revenue is diluted at larger companies. Investors should check the share of revenue from the theme before looking at tickers.

The next question is how much these routes have already contributed to revenue and cash at U.S.-listed companies.

U.S.-Listed Markets Priced Private-Market Money First Through Acquisition Prices and Narrative Multiples

We gathered 2026 second-quarter results and Oct 9 closing prices for about 60 U.S.-listed biotech and medical technology companies. We reviewed quarterly reports filed with the U.S. Securities and Exchange Commission (SEC) and company earnings materials. All stock returns in this section are price returns excluding dividends.

In 2026, traces of private-market money in U.S.-listed biotech stocks appeared first in acquisition prices and high revenue multiples, before they appeared in earnings. The first test of whether those traces reach revenue and regulatory language will come with third-quarter results and FDA decisions in late October.

Biotech Outperformed the Market This Year, but Lagged Over the Past Three Months as Rates Rose

XBI, an exchange-traded fund with a large allocation to small- and mid-cap biotech stocks, gained 26.1% from the start of 2026 through Oct 9. Over the same period, SPY, which tracks the S&P 500, gained 14.2%, while IBB, which has a large allocation to big biotech stocks, gained 22.3%⁵⁴.

Over the past three months, XBI fell 6.4% while SPY gained 3.6%. Large-cap-focused IBB also gained 4.6%, so the weakness was concentrated in XBI, which weights stocks equally, and therefore in small- and mid-cap biotech.

The figure below shows how far biotech indexes moved differently from the broader market year to date and over the past three months.

Recent performance differed between large-cap and small- and mid-cap biotech indexes, so the sector assessment changes depending on which index serves as the benchmark.

The U.S. Federal Reserve raised its policy rate on Sep 16, its first increase since 2023⁵⁵. The 10-year Treasury yield rose from 4.18% at the start of the year to 5.24% on Oct 9⁵⁶.

Based on daily data this year, XBI fell an average of 1.6% on days when the 10-year yield rose by 0.1 percentage point (10 bp). The response was about twice the size of SPY’s (our own calculation). However, rates explain only part of daily moves.

XBI hit its high for the year on Aug 19 and fell 9.3% from that high through Oct 9. Both the 10-year yield and SPY rose over the same period. Rates rose as biotech weakened, but this analysis did not prove that rates caused the weakness. From the start of the year through August, XBI rose even as rates increased. This analysis judges that acquisitions, IPOs, and clinical results outweighed rate pressure during that period.

A basket of nine representative life science tools companies, weighted equally, fell 15.4% from the start of the year through mid-May. Over the past three months, it rose 22.5%, moving in the opposite direction from XBI (our own calculation). Reports linked the move to improving results, but causation was not verified.

The table below summarizes the values, meanings, and source grades for indicators of interest rates, capital flows, and approval pace.

Indicator	Value	Meaning	Source grade
Federal funds rate	3.75~4.00%	Raised 0.25 percentage point on Sep 16, the first increase since 2023	Primary (Federal Reserve)
U.S. 10-year Treasury yield	4.18% → 5.24%	Up 1.06 percentage points from the start of the year, as of Oct 9	Primary (Treasury)
XBI on days the 10-year yield rose 0.1 percentage point	Average −1.6%	About twice SPY’s (−0.8%); causation not proven	Our own calculation
Biopharma acquisitions in the first half	42 deals, $130 billion	Count of deals worth at least $250 million involving majority stakes	Secondary (IQVIA)⁵⁷
U.S. biotech IPOs	25 deals	Through pricing on Oct 8, more than twice the full-year 2025 total	Secondary (BioBucks)⁵⁸
FDA novel drug approvals	46	Based on the Center for Drug Evaluation and Research (CDER), 13 more than at the same point last year	Primary (FDA)⁵⁹

The 46 FDA approvals exclude approvals by the Center for Biologics Evaluation and Research (CBER), which oversees vaccines, cell therapies, and gene therapies. Acquisition and IPO counts also use different scopes across sources, so they should not be added together. The counting criteria need to be aligned before comparing the figures.

High Revenue Multiples Appeared in Stocks Driven More by Narrative Than Growth

The revenue multiple is enterprise value (EV) divided by revenue for the latest four quarters (TTM). EV is market capitalization plus debt minus cash, and this analysis excludes lease liabilities. The multiple shows how many dollars of enterprise value the market assigns to each dollar of revenue.

The figure below plots second-quarter revenue growth on the horizontal axis and this multiple on the vertical axis to show how the market values growth rates. The vertical axis uses a logarithmic scale, and bubble size represents market capitalization. Recursion (RXRX) was excluded because its revenue fell 60% and its 32.9x multiple put it outside the axis range.

At the same growth rate, multiples vary by several times across segments, so choosing comparables based only on growth rates produces a mismatch.

Second-quarter revenue grew 5~10% at Thermo Fisher (TMO), Danaher (DHR), and Illumina (ILMN), with multiples of 6~9.5x⁶⁰. Large tools companies cluster near the center of the figure, where growth rates and multiples are not far apart.

Second-quarter revenue grew 26~44% at GRAIL (GRAL), Natera (NTRA), and Guardant Health (GH), with multiples of 19~33x. Diagnostics is a segment with both high growth and high multiples. GRAIL has the highest multiple of the three, despite an operating loss about four times its revenue⁶¹.

On Sep 23, an FDA advisory committee voted 7 to 2 that the benefits of GRAIL’s Galleri multi-cancer early detection blood test outweigh its risks⁶². The remaining step is the FDA’s premarket approval (PMA) decision, for which no date has been announced. The FDA directly asked the advisory committee whether performance supports the “early detection” label, and the test’s sensitivity for detecting Stage 1 cancers is 13.6~21.4%⁶³.

If approved, Medicare, the U.S. public health insurance program for older adults, could provide coverage starting in 2028. However, the reimbursement benchmark is about $509, based on a figure in Freenome’s (FRNM) listing documents⁶⁴, while GRAIL’s current revenue per test is about $699 (our calculation). This analysis judges that the “early” wording in the approval label and the launch of competing products will determine the diagnostic multiple more than the approval decision itself.

Hinge Health (HNGE) grew second-quarter revenue 53%, but its multiple is 10.9x⁶⁵. Omada Health (OMDA) has a 3.5x multiple⁶⁶. Both companies have growth rates similar to or higher than those of the three diagnostics companies, but their multiples are much lower.

Hinge’s second-quarter operating margin is 19% under U.S. generally accepted accounting principles (GAAP), while Omada’s is 4%. Omada’s membership grew sharply, but revenue per member rose only 2% over the past year. Both companies went public in 2025, and Hinge, with its higher margin, has gained much more than Omada relative to its IPO price.

Insurer Oscar Health (OSCR) grew its membership 46% year over year⁶⁷. However, second-quarter earnings included a one-time gain of $164 million from releasing reserves set aside in prior periods. The company’s earnings power after enhanced Affordable Care Act (ACA) subsidies end in late 2025 needs to be reassessed during the 2027 enrollment period, which typically begins on Nov 1.

10x Genomics (TXG) saw second-quarter revenue fall 12.6%, but its multiple is 16.1x⁶⁸. Excluding the patent settlement received in the same quarter last year, growth was still 3%. Instrument revenue fell sharply, and the company said customers delayed purchases while waiting for Atera, its new spatial biology instrument.

Twist Bioscience (TWST) has an operating margin of −31% and a multiple of 23.4x⁶⁹. Revenue grew 23%, with a large increase in revenue from therapeutics customers. Both companies sell consumables and DNA used to produce biological data at scale for training AI models.

There is little documentary evidence of the AI connection at either company. In an Aug 18 filing, Twist said that after Anthropic published a post describing results from protein design across 15 targets, Anthropic selected Twist as an independent evaluator for the production and binding tests of designed proteins.⁷⁰ For 10x Genomics, the evidence consists only of management comments on earnings calls and analyst notes, both secondary sources. We found no quantitative study that measured the causes of the gains, and the sample is small, so this analysis does not conclude that AI expectations caused the multiples.

Platform Revenue Fell While Data and Software Revenue Grew

The figure below sorts year-over-year second-quarter revenue growth by segment color to show which businesses grew revenue among listed companies in themes that attracted private-market money.

Even within “AI biotech,” revenue trends differ between platforms that receive research collaboration fees and companies that sell data and software, so the business models need to be assessed separately.

Thermo Fisher’s second-quarter organic growth rate, excluding acquisition and currency effects, was 5%, while Danaher’s core revenue growth rate was 3%⁶⁰⁷¹. Organic growth at large tools companies remains in the single digits.

Danaher reported that second-quarter orders for biopharmaceutical production equipment and consumables (bioprocessing) rose by the mid-teens⁷¹. Agilent’s (A) pharmaceutical and biotech revenue for the quarter ended in late July rose 12%, while academic and government revenue fell 3%⁷². Demand from pharmaceutical customers has returned, while demand for U.S. university and government research funding remains weak.

China accounted for 4.8% of Illumina’s revenue, 9.9% of 10x Genomics’, and 12.5% of Bruker’s (BRKR) (calculated from each company’s second-quarter filings). BIOSECURE, which would bar transactions between designated Chinese biotechnology companies and the U.S. federal government, has an initial deadline for the list of companies of concern around Dec 18⁷³. A law firm analysis says actual transaction bans would come later, after guidance and procurement rules are revised.

Second-quarter revenue at AbCellera (ABCL), Recursion, Absci (ABSI), and Generate Biomedicines (GENB) fell 38% to 76% from a year earlier. Partner revenue recognized from research collaborations with pharmaceutical companies declined. Recursion said revenue fell because some stages of its Roche projects ended⁷⁴.

Second-quarter revenue at Caris Life Sciences (CAI) rose 45%. Tempus AI (TEM) rose 22%, and Schrödinger (SDGR) rose 8%. These companies sell recurring products such as molecular profiling tests and data, clinical data, and molecular design software.

Schrödinger’s second-quarter net income of $6 million came from a one-time event. Eli Lilly (LLY) acquired Ajax, which Schrödinger co-founded, and Schrödinger received $57.2 million in equity proceeds and milestone payments⁷⁵. Its core business still had an operating loss of $41.5 million.

In large pharmaceutical contracts confirmed against original documents, upfront payments at signing were 3% to 6% of the announced total (this analysis’s calculation). The rest is payable only when development, regulatory, or sales conditions are met, and public companies rarely include these contingent amounts in accounting revenue forecasts⁷⁴. Platform companies have received more cash from one-time sources such as equity realizations, settlements, and capital raises than from recurring revenue.

AbCellera’s share price rose 267% year to date after an August Phase 2 announcement, an intermediate clinical trial stage that first checks for efficacy. Absci rose 191%. Recursion, which depends on partner revenue, rose 6.6%, below XBI’s gain⁵⁴. This year, clinical events, rather than platform revenue, have driven share prices of AI drug discovery companies.

On Sep 23, the FDA approved lirafugratinib, a bile duct cancer treatment designed using molecular dynamics simulation by Relay Therapeutics (RLAY)⁷⁶. The approval holder is Elevar, a U.S. subsidiary of South Korea’s HLB, according to reports⁷⁷. Relay is the licensor that granted technology rights and receives milestones and royalties. Relay has received $18.7 million to date, and contractual milestones total up to $485 million⁷⁸.

This approval is based on physical simulation, not generative AI, and an approved drug already exists for the FGFR2 target. The evidence points to a more selective molecule against the same target, not to the discovery of a new target. Takeda’s zasocitinib, designed by Nimbus using the Schrödinger platform, was also accepted for priority review on Sep 14. The target date for an approval decision is the first quarter of 2027⁷⁹.

No U.S.-listed AI drug discovery company has yet filed for approval of its own asset. The most advanced internally owned asset is in Phase 3, the final clinical stage before approval, and results are not expected until after 2028.

Alphabet-affiliated Isomorphic Labs raised $2.1 billion in a single round in May, according to reports⁸⁰. The EVs of listed AI drug discovery companies are $1.4 billion to $3.5 billion (calculated). Generate, which went public in February, was trading 10% below its IPO price as of Oct 9.

Drug company valuations hinge on multiples of cash and binary events

Drug companies have little revenue, so this analysis looks at market capitalization divided by cash as of June 30. Cash is cash and cash equivalents plus marketable securities. A multiple of 1x means the market assigns almost no value to drug candidates beyond the company’s cash.

The figure below shows how much more than cash the market assigns to each company’s drug candidates.

The lower the multiple, the more cash provides a cushion if a clinical trial fails. The higher the multiple, the more expectations rest on the next result.

BioAge Labs (BIOA), which emphasizes aging, trades at 0.76x, with a market capitalization below its cash. Its EV is about −$90 million⁸¹. The primary endpoint in its ongoing Phase 2 trial is hsCRP, an inflammation marker, not an aging measure.

Companies with late-stage assets generally trade at 1x to 3x cash. BioNTech (BNTX) at 1.31x and Intellia (NTLA) at 2.91x are in this range. They have commercial products or assets in Phase 3 or at the regulatory filing stage.

AI drug discovery companies trade at higher multiples: 4.3x for Recursion, 7.2x for AbCellera, and 8.7x for Absci. This analysis interprets those valuations as higher than those of companies with late-stage assets, with a substantial share of their value resting on the next clinical result and the platform narrative.

Moderna (MRNA) is highest in the figure at 13.0x. On Aug 19, the day Moderna announced that its personalized mRNA cancer therapy, developed with Merck, met the primary endpoint in a Phase 3 melanoma trial, Moderna’s share price rose 177% in one day⁸². The Phase 3 effect size, measured by the hazard ratio, has not yet been disclosed.

United Therapeutics (UTHR) is also at 6.2x, but its value has a different basis. Its pulmonary arterial hypertension drug business, which generated $333 million in second-quarter net income, supports its valuation. Xenotransplantation revenue is still zero⁸³. This analysis views the value of xenotransplantation as layered on top of a profitable business rather than priced separately.

Based on first-half cash burn, Recursion has about 1.5 years of cash, Generate about 1.7 years, and Absci about 1.9 years. These estimates divide June-end cash by first-half operating cash outflow annualized.

The companies have given longer runways. Recursion said it expects to fund operations into early 2028, and Absci into the second half of 2028. Those figures assume cost reductions and contract payments⁷⁴. This analysis sees cash burn as determining the downside for companies whose clinical results fall short of expectations when interest rates are rising.

A binary event is one with two possible outcomes: success or failure. The largest dated binary event is Intellia’s approval decision for lonvo-z, a treatment for hereditary angioedema. It is the first approval decision for a CRISPR gene-editing therapy that alters genes inside the body. The PDUFA, or FDA target date for an approval decision, is Mar 10, 2027⁸⁴. The FDA told the company it does not plan to hold an advisory committee meeting.

Private valuations flow out through acquisitions and appear as multiples in public stocks

The figure below shows how strongly private-company value reaches public-company results through each theme. It labels routes strong when confirmed by actual transactions, revenue, or legal and regulatory processes; medium when only partly confirmed; and weak when no cases exist or the process is delayed. These strength ratings are this analysis’s judgment.

The route varies by theme. Even within biotech, investors need to identify public companies and confirmation methods separately for each theme.

Four of the five routes are strong for diagnostics and screening. Evidence includes Abbott’s acquisition of Exact Sciences; competition between Abbott and Guardant in blood tests for colorectal cancer; Freenome’s SPAC merger and listing; and a law that allows Medicare to cover multi-cancer early detection starting in 2028.

For cell, gene, and organ therapies, the acquisition and regulatory routes are strong. Evidence includes Lilly’s acquisition of a private in vivo CAR-T company, which changes immune cells directly inside the patient’s body, and Intellia’s approval decision deadline. For tools and measurement, the acquisition and supply-chain routes are strong, while the competition, listing, and regulatory routes are weak.

AI drug discovery is generally medium, while its supply-chain and regulatory routes are weak. For digital health, only the listing route is strong, thanks to Hinge and Omada going public. For medical AI, only the competition route is strong.

No U.S.-listed company focuses only on AI for medical documentation. Epic, a private electronic health record company, launched the same function directly in February⁸⁵. Doximity (DOCS), a physician network, has fallen 58% over the past year amid discussion of competition from free medical AI. For public investors, the theme has reached them first through competition rather than as a benefit.

Both routes are weak for brain-computer interfaces (BCI) and aging. This research found no IPO filing or announced SPAC merger by a U.S. private brain-computer interface company. No listed company focused on aging has a clinical trial where aging itself is the indication.

IQVIA’s tally, which counts only transactions above $250 million, recorded 42 biopharma acquisitions worth $130 billion in the first half of 2026⁵⁷. That is close to the total for all of 2025. Acquisitions are the route by which private-company value has most often been confirmed entering public markets through actual transactions.

Lilly acquired $26 billion worth of companies in the first half alone, according to IQVIA, and 10 of its 13 acquisition targets this year are private companies.⁸⁶⁸⁷ In vivo CAR-T companies Kelonia and Orna are among them. This is a route for private-company value to flow directly to large pharmaceutical companies without passing through publicly traded biotech companies.

Lilly’s market capitalization was $1.11 trillion on Oct 9. Individual acquired assets are small by comparison, so the theme gives Lilly shareholders limited exposure. For public-market investors, the direct share of this route is the premium paid to shareholders of acquired public biotech companies.

Based on BioBucks’ deal table, the median premium (the amount by which the acquisition price exceeded the prior share price) for 15 acquisitions by strategic buyers of public biotech companies was about 41%.⁸⁷ The range was 2% to 140%. The figures mix prior closing prices and average share prices over specified periods, so they are reference points. Across all 24 disclosed public-company targets in 2026, the median disclosed premium was about 39%. When a late-stage small or mid-cap company trading near its cash value is acquired, its shareholders receive this premium. Whether an acquisition will happen is unknown. This analysis establishes that such deals have occurred.

Acquisition prices for tools and diagnostics companies provide another reference point for gauging public-market valuations. The table below lists 2026 deals by the acquisition price as a multiple of the target company’s revenue.

Acquirer → target	Target company	Revenue multiple	Deal status
Repligen → Biolife Solutions	Cryopreservation media for cell therapies	About 14.6x	Closed on 2026-10-06⁸⁸
Merck KGaA → Bio-Techne	Research reagents and instruments, $73 per share	About 9.3x	Expected to close in late 2026 to early 2027⁸⁹
Abbott → Exact Sciences	Cancer diagnostics	About 7x	Closed on 2026-03-23⁹⁰
Blackstone and TPG → Hologic	Diagnostics and medical devices	About 4.5x	Closed on 2026-04-07⁹¹
Altaris → Simulations Plus	Drug development software	About 4.1x	Closed on 2026-10-06⁹²
Tempus → Personalis	Cancer recurrence monitoring tests	More than 20x	Agreement signed in July 2026, not yet closed⁹³
Market multiples for listed large tools companies	Thermo Fisher, Danaher, Illumina, etc.	6.1x to 9.5x	Based on closing prices on 2026-10-09

The higher multiples were attached to companies with more recurring revenue, such as those selling consumables and reagents. This is this analysis’s interpretation. The multiples are this analysis’s calculations, dividing announced deal prices by the targets’ most recent revenue. The revenue periods therefore differ slightly across deals.

The same tracking table shows 19 acquisitions in the third quarter, fewer than the 33 in the second quarter. Only one acquisition was announced in September. Some deals may be missing from the tracker. The period overlaps with a sharp rise in interest rates, but no causal link has been established.

The confirmation points for the next six months cluster around late-October earnings and a March 2027 regulatory decision

The table below lists earnings reports, binary events, and policy dates scheduled from Oct 10 through early April 2027. The final column distinguishes dates confirmed by a company or government agency from dates confirmed only by media reports.

Month	Date	Event	Type	Date source
October	20	Intuitive’s third-quarter earnings	Earnings	Company announcement⁹⁴
October	21	Thermo Fisher, Danaher, and Abbott third-quarter earnings	Earnings	Company announcements⁹⁵⁹⁶⁹⁷
October	22	Quest Diagnostics (DGX) third-quarter earnings	Earnings	Company announcement⁹⁸
October	23-27	European Society for Medical Oncology (ESMO); Moderna’s detailed Phase 3 results on the 24th	Binary event	Conference and company announcements⁹⁹
October	25	Insilico (Hong Kong-listed) oral presentation of Phase 1 results at ESMO	Binary event	Company announcement¹⁰⁰
October	27-28	Federal Reserve monetary policy meeting	Policy	Federal Reserve calendar
October	29	Illumina and Lilly third-quarter earnings	Earnings	Media reports
November	2	Hinge Health third-quarter earnings; Recursion’s additional REC-4881 results	Earnings and binary event	Company announcement¹⁰¹
November	3 and 9	BioNTech (3rd) and AbCellera (9th) third-quarter earnings	Earnings	Company announcements
November	5	Tecan (Swiss-listed) third-quarter qualitative update	Earnings	Company announcement¹⁰²
November	12	Moderna investor briefing	Earnings (company event)	Company announcement
November	30	Most-Favored-Nation drug pricing model GLOBE takes effect (under litigation; implementation begins in January 2027)	Policy	Federal Register¹⁰³
November	30	Deadline to publish third-round Medicare drug negotiation prices	Policy	Statutory deadline
December	8-9, 11, 18	Federal Reserve meeting, expiration of government continuing resolution, and first Biosecure Act list deadline	Policy	Federal Reserve calendar and law (law firm analysis for list deadline)
March 2027	10	Intellia lonvo-z regulatory decision deadline	Binary event	Company filing

The FDA’s final decision on Grail testing was omitted because no date has been made public. Takeda’s decision for zasocitinib is known only as the first quarter of 2027. Regulatory decision dates on tracking sites should be checked against company filings. One tracker lists tavapadon in December, but the FDA already approved it on Sept 25.⁵⁹

The near-term confirmation points are late-October tools and diagnostics earnings and Moderna’s detailed results. The largest scheduled binary event is in March, after the turn of the year. Until then, valuations on the therapeutics side depend more on cash and interest rates.

Earnings drive research judgments for tools and diagnostics, while binary events drive them for therapeutics

The key takeaway in the table below is the sentence with the strongest evidence in this research. The confirmation trigger is a dated event that can show whether the sentence holds. A reversing signal is an event that would require revising the key takeaway.

Area	Key takeaway	Confirmation trigger	Reversing signal
Tools, measurement, and manufacturing	Pharmaceutical demand has recovered, and the AI narrative accompanies some high multiples, but revenue confirmation is lacking	Oct 21: Thermo Fisher and Danaher; Oct 29: Illumina earnings, including bioprocessing orders	Reduced academic and government demand offsets pharmaceutical recovery; first Biosecure Act list in December
AI drug discovery and design	Designed molecules have reached approval, but no public company has filed an approval application for its own drug, and cash remains a one-time funding source	Nov 2: Recursion’s additional results; Absci’s mid-stage proof of concept for hair loss (second half of the year)	Upfront payments remain 3% to 6% of total contract value; new listings continue to trade below IPO prices
Diagnostics and screening	This is a high-growth, high-multiple area. Label wording and competitive launches shape value more than approval status	Grail’s PMA decision wording; Abbott’s launch results for the Freenome test; Guardant’s quarterly test volume	Removal of the “early” label or cancer-type warnings; gap between the reimbursement benchmark of about $509 and revenue per test of about $699
Digital health and medical AI	Earnings quality determined performance, and Epic’s built-in documentation AI is a competitive route without a listed proxy	Nov 2: Hinge earnings; Omada revenue per member; November ACA enrollment period	Confirmation that Oscar’s earnings relied on a one-time reserve reversal; intensifying competition from free medical AI
Therapeutics and cell and gene therapy	Binary events determine value. Acquisition cases carried premiums when cash was 1x to 3x value	Oct 24: Moderna’s detailed results; Mar 10, 2027: Intellia regulatory decision	Prolonged FDA commissioner vacancy and reduced review staff; gap in vaccine recommendations; trial hold after a death
Brain interfaces and aging	Listed proxies have zero BCI revenue or revenue from other businesses. First-in-human results come first	ONWARD’s first human bladder trial (second half of the year); BioAge Phase 2 results; IPO filing by a private BCI company	No signal yet; reclassify if the first IPO filing appears

Brain interfaces, aging, and xenotransplantation are themes that have attracted substantial private funding, but listed proxies have zero revenue from these areas. By contrast, some tools and diagnostics stocks have high multiples alongside AI and early-screening narratives. Third-quarter earnings and Grail’s regulatory decision are the first tests of whether these narratives translate into revenue and label language. While interest rates are rising, I expect cash burn to determine the downside for companies that fail this test. These key takeaways and signals reflect this analysis’s research judgment, based on comparables and confirmation dates. They are not a recommendation to buy or sell any security.

Only two Korean listed companies have both disclosed overseas contracts and profits under the same yardstick

We apply the same criteria to Korean listed companies as we do to the global map. Do they solve bottlenecks in measurement, experimentation, cell manufacturing, or medical workflows that customers around the world pay to address? The figure shows which of 22 companies have evidence of overseas customers, profits, and revenue sources that fit the theme. It arranges facts verified through OpenDART filings and news reports as of Oct 10, 2026. It is a map for deciding where to start research, not a stock-picking table.

The three boxes, from left to right, show evidence of overseas customers, whether the company was profitable in the first half of 2026, and whether its revenue sources fit the theme. Dark teal means an overseas contract appears in a filing, the company was profitable, or its revenue source fits the theme. Light ochre means the evidence comes from a news report or company announcement, or only partly overlaps with the theme. A dotted outline means evidence is absent, activity is centered in Korea, or the company is loss-making. Dark red means its largest revenue source comes from a business outside the theme.

We grouped the companies into five categories: automation and measurement, cell and biomanufacturing, proprietary experimental data, medical AI and workflows, and diagnostics and screening. The bars on the right show first-half 2026 revenue on a logarithmic scale, so the length differences appear smaller than the actual differences. This allows Samsung Biologics, with KRW 2.578 trillion in revenue, and Oncocross, with KRW 230 million, to fit on one screen. Dark bars mark companies with positive operating income in the first half.

No company has three dark boxes. Samsung Biologics and ST Pharm are the only two companies with overseas contracts confirmed in filings and first-half profits.¹⁰⁴¹⁰⁵ However, both provide contract manufacturing for antibodies and oligonucleotides, so their revenue sources only partly overlap with the theme. ENCell, in the same category, has a dotted overseas box because its disclosed 2026 contract counterparty was a domestic developer.¹⁰⁶

Seegene and Seers Technology were profitable, and their revenue sources fit the theme, but their overseas evidence comes from news reports. The reported 57.2% European share of Seegene’s second-quarter revenue is a news figure. Most of Seers Technology’s revenue comes from domestic hospital installations.¹⁰⁷¹⁰⁸

Evidence grades vary among loss-making companies. News reports put Lunit’s overseas revenue share at 95% in the first half, while its operating loss was KRW 28.96 billion.¹⁰⁹ In the diagnostics and screening category, Noul is the only company with an overseas contract confirmed in a filing: it supplied KRW 1.1 billion worth of products to Panama.¹¹⁰

The figure suggests an order for research: start with companies that meet two of the three conditions, then make the missing condition a diligence question. For an automation company such as Curiosis, which has an overseas filing, ask about its path to profitability. For Samsung Biologics and ST Pharm, ask whether they have revenue that connects to the theme. Seegene and Seers Technology still need their overseas customer evidence confirmed in filings.

The first-priority diligence types are companies in Korea with revenue still of only a few billion won

The cell and experimental automation types marked for first-priority diligence on the global map are also present in Korea. Curiosis, IBEAM Technology, Protina, Excel Therapeutics, CuriOx Biosystems, and Microdigital have evidence of selling measurement equipment and services, or cell-manufacturing materials, to overseas customers. But their first-half 2026 revenue ranged from KRW 520 million to KRW 4.62 billion, and all reported operating losses.

The strongest evidence comes from companies whose filings disclose the contract counterparty and amount. In January 2026, Curiosis disclosed an ODM contract with Revvity’s Chinese subsidiary for colony pickers. ODM means the manufacturer develops and produces a product that the customer sells under its own brand. The contract was worth $1.48 million, or about KRW 2.18 billion. The company said the contract uses a minimum-purchase arrangement, so actual revenue depends on orders.¹¹¹

In September 2026, IBEAM Technology disclosed two supply contracts for intravital microscopes. The contracts go through a Canadian distributor, but the end customers are the US National Institutes of Health’s NIEHS and Yale University.¹¹² According to a news report, all KRW 2.79 billion in intravital microscope revenue in the first half came from exports. The company stated in its semiannual report that purchase decisions typically take about two years.¹¹³

In September 2025, Protina disclosed a $850,000 contract to analyze clinical specimens for a US multinational pharmaceutical company.¹¹⁴ Yet its first-half 2026 revenue was KRW 520 million, about 18% of its 2025 full-year revenue. This shows that a single contract does not ensure steady recurring revenue.

News reports confirm Excel Therapeutics’ culture-media supply to China’s Shanghai Cell Therapy Group and its white-label contract with Germany’s PL BioScience, under which products are sold under the counterparty’s brand.¹¹⁵ Its first-half 2026 revenue of KRW 2.96 billion already exceeded its full-year 2025 revenue of KRW 1.95 billion. However, its total equity at the end of June was only KRW 4.33 billion, so its growth rate and funding capacity should be assessed together.¹¹⁶

Microdigital corrected its disclosure to state that cumulative payments under its supply contract with Japan’s Shinkou Seiki totaled KRW 690 million. Its bioreactor supply to India’s Serum Institute is supported by news reports.¹¹⁷ Cash and cash equivalents at the end of June were KRW 5.11 billion. Even including short-term financial instruments, this was below its first-half operating loss of KRW 9.23 billion.¹¹⁶

CuriOx Biosystems’ claim that it supplied 18 of the world’s top 20 pharmaceutical companies came from a company announcement at its 2023 listing. News reports say its annual revenue fell from KRW 6.8 billion in 2023 to KRW 5.2 billion in 2025. The number of customers still purchasing from the company needs to be checked separately.¹¹⁸

The key question for this group is whether an initial contract leads to repeat orders. For equipment companies, examine the share of revenue from consumables. For minimum-purchase contracts, check the order fulfillment rate against the committed volume. Curiosis’ KRW 2.08 billion public procurement contract bundled third-party equipment with its own, so the two revenue sources should be separated.¹¹⁹

Filings and contract counterparties distinguish companies whose revenue sources differ from their theme labels

Syntekabio is known as an AI drug discovery company, but its largest contract is for data center leasing. Its July 2026 filing disclosed a KRW 6.48 billion colocation contract with Ato Research, equivalent to 189% of its latest annual revenue.¹²⁰ A September 2026 filing disclosed an AI antibody optimization contract worth KRW 530 million, covering antibodies for dogs.¹²¹

Deepnoid is classified as a medical imaging AI company, but research materials say industrial machine vision accounted for 86.1% of its 2024 revenue. Its largest disclosed contract was also for an industrial project: a KRW 7.5 billion vision system for secondary batteries.¹²² That is why the boxes for Deepnoid, Syntekabio, and Voronoi are dark red in the figure.

Voronoi and PharosiBio promote AI drug-design platforms, but their actual business is clinical development of their own drugs. Voronoi had no revenue in the first half of 2026 and reported an operating loss of KRW 51.30 billion.¹²³ PharosiBio had no revenue account in its 2025 annual report.¹²⁴ Neither company earns money from data or services, so this framework treats them separately as drug developers.

Bioneer was considered because it has molecular diagnostic equipment, but it was excluded from the candidates. An April 2026 research report stated that 93% of its current revenue comes from a subsidiary’s diet probiotic brand.¹²⁵ Classifying companies by disclosed contract counterparties and amounts, rather than by their names or stated technologies, reveals these differences.

The confirmation question for most companies is whether a single contract turns into recurring revenue

The table answers where each group’s revenue comes from and what to ask in the next diligence round. We selected 13 of the 22 companies in the figure and added PharosiBio, which is not shown.

Group	Company (Code)	Where Revenue Comes From	Evidence of Overseas Customers	Revenue / Operating Profit (FY25 → H1 26)	Questions to Check
Automation and measurement	Curiosis (494120)	Cell imaging and colony-picking equipment	$1.48 million from Revvity China ODM (filing)	73.0 / −75.3 → 46.2 / −34.8	Actual orders versus contracted volume; equipment revenue excluding public procurement
	IBEAM Technology (460470)	Intravital microscopy	NIEHS and Yale University as end customers (filing); all exports in H1 (press report)	43.8 / −41.5 → 30.5 / −16.5	Impact of changes in US research budgets on orders; conversion rate from demos
	Protina (468530)	Protein interaction measurement services	$850,000 from a US multinational pharmaceutical company (filing)	29.5 / −113.7 → 5.2 / −86.7	Repeat revenue by customer; data ownership and reuse rights
	Excel Therapeutics (373110)	Cell culture media for cell therapies	Shanghai Cell Therapy Group in China and PL BioScience in Germany (press reports)	19.5 / −108.5 → 29.6 / −56.7	Share of media used in therapies at the commercial stage
	CuriOx Biosystems (445680)	Automated cell-washing equipment and consumables	18 of the top 20 pharmaceutical companies (company announcement, 2023)	51.5 / −123.1 → 25.0 / −77.1	Current number of active customers and repurchase rate
	Microdigital (305090)	Single-use cell culture bioreactors	Shinkou Seiki (filing); Serum Institute (press report)	128.4 / −91.7 → 36.6 / −92.3	Repeat orders from vaccine makers; consumables share
Cell and biopharmaceutical manufacturing	Samsung Biologics (207940)	Antibody CDMO (contract development and manufacturing)	$68.75 million from a European pharmaceutical company (filing)	45,569.7 / 20,692.2 → 25,780.3 / 11,672.0	Peptide order backlog after the PolyPeptide acquisition
	ST Pharm (237690)	Oligonucleotide API CDMO	$66.1 million from a US biotech company (filing)	3,316.8 / 549.3 → 1,754.5 / 298.4	Share of top three customers; renewal terms for commercial products
Proprietary experimental data	Syntekabio (226330)	AI discovery services and data center leasing	The counterparty to the 2026 disclosed contract is domestic	34.3 / −107.6 → 8.7 / −57.3	AI services revenue excluding leasing
	Voronoi (310210)	Proprietary drug development and licensing	Candidate compound transferred to US-based Anvia (2025, press report)	75.1 / −543.8 → 0.0 / −513.0	Source of 2025 revenue; cash burn timeline
	PharosiBio (388870)	Proprietary drug development; no revenue	At the technology licensing negotiation stage (press report)	None / −115.1 → None / −46.5	Has an external party validated the platform’s contribution?
Medical AI and workflow	Deepnoid (315640)	Industrial machine vision and AI for chest X-ray interpretation	No evidence of overseas medical revenue	74.7 / −105.6 → 16.7 / −72.8	What is revenue from the medical segment alone?
	Lunit (328130)	AI for cancer screening images	KRW 43.4 billion in overseas revenue in H1, or 95% of total (press report)	831.3 / −831.0 → 457.7 / −289.6	Share of recurring revenue; revenue from products reimbursed in the US
Diagnostics and screening	Seegene (096530)	Multiplex pathogen PCR reagents and equipment	Europe was 57.2% and Korea 6.4% in Q2 (press report)	4,742.3 / 345.5 → 2,651.0 / 451.4	Recurring reagent revenue relative to the installed equipment base

Financials are in KRW 100 million and were retrieved through the OpenDART financial statement API on Oct 10, 2026.¹¹⁶ FY25 uses consolidated figures from the 2025 annual report, while IBEAM Technology, Protina, Microdigital, and Deepnoid use standalone figures. H1 26 is the six-month cumulative amount in the 2026 half-year report. Stock prices and market capitalization were not checked.

The companies in the cell and biopharmaceutical manufacturing group differ in size from those in the other groups. A press report says ST Pharm had an oligonucleotide order backlog of about $300 million at the end of June, with commercialized products accounting for about 80%.¹²⁶ Samsung Biologics is proceeding with its acquisition of Swiss company PolyPeptide, making peptide order backlog a new item to check.¹²⁷

The questions differ by group, even when overseas contracts are involved. For equipment companies, the questions are about consumables and repeat purchases. For manufacturers, they are about customer concentration and order backlog. For medical AI, they are about recurring revenue and reimbursement. Seers Technology, which is omitted from the table, is the only profitable medical AI company, but the overseas evidence consists of one press report about a supply deal worth about KRW 22 billion in the UAE.¹⁰⁸

Brain interfaces, aging, molecular design AI, and consumer screening are accessible only through private companies

Some themes attracting money from tech leaders have no route to Korean listed companies. We found no KOSPI or KOSDAQ listed company generating revenue from brain interfaces. Ybrain is private, while Remed makes transcranial magnetic stimulation (TMS) devices and operates in an adjacent neuromodulation field.¹¹⁶

Aging is not an approved indication in Korea, so no listed company generates revenue from aging itself. There is also no pure-play listed proxy for molecular design AI. Galux is private, while Syntekabio’s antibody optimization service and Protina’s antibody design solution provide only limited exposure.¹¹⁶

There is also no listed company with a consumer-facing preventive health screening platform like Neko Health. Genomictree’s early screening reagents and press reports about Seers Technology’s UAE screening business provide partial exposure.¹⁰⁸ These themes are accessible only through private-company sourcing, so for listed companies using the same labels, revenue sources should be checked first.

The next checkpoints are the Oct 12 tender offer deadline and Q3 reports in mid-November

We selected only the remaining 2026 dates that could change the colors in the figure or the numbers in the table. These are the scheduled dates stated in filings or press reports.

Date	Company	What to Check	Evidence
Oct 12 (local time)	Samsung Biologics	PolyPeptide tender offer results; condition that the tender rate exceed 66.7%	Press report¹²⁷
Nov 1	Syntekabio	Start of data center leasing revenue	Filing¹²⁰
Mid-November	All companies	Q3 reports; retrieve all financial figures again	Regular filings
Nov 17	Samsung Biologics	Payment for the rights offering	Filing and press report¹²⁸
Nov 30	IBEAM Technology	Equipment installation and inspection at Yale University	Filing¹¹²
Dec 10	Vuno	Payment for the rights offering (postponed in amended filing)	Filing¹²⁹
Dec 20	Noul	Receipt of the balance for the Panama contract	Filing¹¹⁰

After these dates, Samsung Biologics’ business mix and smaller companies’ loss rates can be reassessed with updated figures.

In the Korean landscape, watch for financing needs and large losses at smaller companies

The first-priority diligence names in Korea are early-stage listed companies with revenue of only a few billion won, so financing risk is closer at hand than for global private-company candidates. In 2025, SD Biosensor reported a net loss of KRW 513.4 billion, while GC Cell reported a net loss of KRW 273.5 billion due to goodwill impairment.¹³⁰¹³¹ LabGenomics also reported an operating loss of KRW 53.5 billion.¹³² The financials include only half-year reports. They should be retrieved again when Q3 reports are published in mid-November.

What Changes the Judgment Is Numerical Evidence, Not Participation by a Famous Investor

Across every cell in the map, the evidence that would change the judgment is the same: effects in independent human studies, productivity that can be reproduced, contract cash actually received, and enough funding to last until the next validation. A rising share price is not one of these four.

The near-term checkpoints are clear. From Oct 21 to 29, check whether bioprocessing orders increased in the third-quarter results from Thermo Fisher, Danaher, and Illumina. Hinge Health’s results on Nov 2 will show whether earnings quality is holding up. In mid-November, check the Korean listed companies’ third-quarter reports to see whether overseas contracts have turned into recurring revenue. Grail’s FDA decision date has not been announced, but whether the authorization language retains “early” will determine the diagnostic valuation multiple. Intellia’s Mar 10, 2027, decision deadline is the largest dated binary event.

What This Analysis Could Not Confirm

This analysis is based on public sources. It did not obtain valuations, shareholder registers, cash balances, or original contracts. It therefore does not assess any individual company’s investment value or the timing of a trade.

The investment links rely on media reports and official portfolio lists. Individual investment amounts and current ownership stakes remain unconfirmed in most cases. An investment not found in the search was not judged to be nonexistent.
The placement of the thematic map and the strength of each route are judgments in this analysis. They are not measurements, and placements could differ under other criteria.
Acquisition counts, IPO counts, and premiums rely on secondary compilations. Their scopes vary, so they were not added together.
Some dates, including Illumina and Lilly earnings dates and the first deadline for the Biosecure Act list, are based on media reports or law firm analyses. They should be checked against company disclosures.
Regional revenue shares for Korean companies in 2026 were mostly not verified against the original semiannual reports. Stock prices and market capitalizations were not checked for Korean companies.
All financial figures should be checked again when third-quarter reports are released in mid-November.

Disclaimer: This material is for research and informational purposes. The companies, multiples, and conditions are analytical examples, not trading recommendations. Readers should conduct their own review before making investment decisions.

Google, announcement of Calico’s founding, 2013-09. This is an example of a company-level founding by Google. ↩︎
Ambience Healthcare, announcement of a $243 million Series C, 2025. A connection to the OpenAI Startup Fund is not evidence of Altman’s personal investment. ↩︎
Reuters, report on OpenAI removing Altman’s ownership of its startup fund, 2024-04-01. ↩︎
Khosla Ventures, Portfolio, accessed 2026-10-09. The official list shows investment connections, but does not prove Khosla’s personal investment, current holdings, or the timing of investments. ↩︎
Bezos Expeditions, official portfolio, accessed 2026-10-09. Individual investment amounts are not disclosed. ↩︎
Chan Zuckerberg Initiative, Ventures list, accessed 2026-10-09. This is a list of equity investments, distinct from the nonprofit research support provided by Biohub. ↩︎
Neko Health, announcement of a $700 million Series C, 2026-07-15. The 75% is the share of appointments booked and prepaid, as reported by the company. It is not an independently verified figure. ↩︎ ↩︎
Neuralink, Neuralink raises $650M Series E, 2025-06-02. ↩︎ ↩︎
GRAIL, announcement of full results from the NHS-Galleri trial (2026 ASCO), 2026-05. This is a company press release. ↩︎
Reuters, report on GRAIL’s blood cancer test (published by Yahoo Finance), 2026-10-02. This is a follow-up report on the advisory committee meeting held on Sep 23, not a final approval decision. ↩︎
Retro Biosciences, 2026 fundraising announcement, 2026-05-22. The amount raised in the follow-on round has not been disclosed. ↩︎ ↩︎
Unity Biotechnology, SEC Form 8-K, 2025. The effective date of dissolution is 2025-09-26. ↩︎
Forbes, report on Unity Biotechnology raising $116 million, 2016-10-27. Attribution to Bezos Expeditions is based on reporting. ↩︎
TTAM Research Institute, announcement of its acquisition of 23andMe assets, 2025. ↩︎
TechCrunch, report on Sergey Brin’s loan of funds to 23andMe, 2009-06-18. ↩︎
Reuters, report on the US government and Google joining Biohub’s $1.8 billion AI biology initiative, 2026-10-07. This is a nonprofit initiative, not a company funding round. ↩︎
Gordian Biotechnology, announcement of collaboration with Pfizer to discover in vivo obesity targets, 2026. The announcement month and contract amount have not been confirmed. ↩︎
MIT Technology Review Italia, report on Altman’s $180 million investment in Retro. The publication date has not been confirmed, and attribution to Altman personally is based on reporting. ↩︎
NewLimit, announcement of a $435 million Series C, 2026. The timing of the first human trial is a company plan. ↩︎
Altos Labs launch announcement (PR Newswire), 2022. The $3 billion is the total amount committed, not Bezos’s personal investment. ↩︎
Goodwin, announcement of its advisory role in LifeMine Therapeutics’ $263 million funding round, 2026-08. The $263 million is the combined total of Series D and E. ↩︎ ↩︎
VCA, report on Synchron’s $200 million Series D, 2025-11. ↩︎
OpenAI, Investing in Merge Labs, 2026-01-15. Altman’s personal investment amount has not been disclosed. ↩︎
Celgene, first-quarter 2018 report (SEC Form 10-Q), 2018. Juno’s acquisition was completed on 2018-03-06. Individual investors’ returns have not been confirmed. ↩︎
Gates Foundation SIF, Kymab, accessed 2026-10-09. ↩︎
Gates Foundation SIF, Affinivax, accessed 2026-10-09. ↩︎
BioSpace, report on AbbVie’s $5.8 billion acquisition of Stemcentrx. The publication date could not be confirmed. ↩︎
AbbVie, announcement of the discontinuation of the Rova-T research and development program, 2019-08-29. ↩︎
Until Labs, announcement of $58 million Series A (GlobeNewswire), 2025-09-22. ↩︎
Abbott, Abbott completes acquisition of Exact Sciences, 2026-03-23. The total transaction value is omitted because reports differ. ↩︎
Lilly announcement, Lilly completes acquisition of AtaiBeckley (published by Finviz), 2026-09-11. This site republishes the company announcement. ↩︎ ↩︎
Quest Diagnostics, WHOOP to Bring Clinical Lab Testing from Quest Diagnostics to the WHOOP App, 2025-09-18. ↩︎
HLTH, Epic releases native AI charting, 2026-02-06. This is a news source. ↩︎
Microsoft, Microsoft Dragon Copilot meets the moment at HIMSS 2026, 2026-03-05. ↩︎
Hinge Health, Hinge Health Announces Pricing of Initial Public Offering, 2025-05. ↩︎
Generate Biomedicines, Generate Biomedicines announces pricing of initial public offering, 2026-02. ↩︎
SEC, Freenome prospectus related to the securities registration (424B3), 2026. ↩︎
Freenome, FDA approves Freenome’s SimpleScreen CRC, 2026-07-27. ↩︎
Rep. Terri Sewell, Signing of the Nancy Gardner Sewell Multi-Cancer Early Detection Act, 2026-02. ↩︎
MD+DI, FDA advisory panel narrowly backs multi-cancer blood test despite effectiveness concerns, 2026-09. This is a news source. Some reports appeared on Oct 2, but the meeting was held on Sep 23. ↩︎
Business Wire announcement, UnitedHealth Group now covers Guardant Health’s Shield blood test (published by Chartmill), 2026-07-01. Inclusion in American Cancer Society guidelines is based on the company’s 2026-05-26 announcement. ↩︎
Takeda, U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib, 2026-09-14. ↩︎
BioNTech, BioNTech closes acquisition of CureVac N.V., 2026-01. The original source confirming the delisting’s effective date could not be confirmed. ↩︎
NYSE, NYSE to Commence Delisting Proceedings Against Vicarious Surgical, 2026-03-03. ↩︎
SEC, Unity Biotechnology Form 8-K, 2025. ↩︎
23andMe, announcement of TTAM Research Institute asset acquisition, 2025-07. ↩︎
ONWARD Medical, First Half 2026 Results, 2026-09-09. ↩︎
Synchron, Synchron Raises $200 Million Series D, 2025-11-06. ↩︎
SEC, BioAge Labs earnings release (Form 8-K exhibit), 2026. ↩︎
Quiver Quantitative, Longeveron Announces ELPIS II Results, 2026-09-16. This is a secondary source reproducing the company announcement. ↩︎
SEC, United Therapeutics Q2 2026 earnings release, 2026-08-05. ↩︎
HLTH, Neko Health raises $700 million, 2026-07. The finding that there is no listed proxy is based on a search. ↩︎
IFR, Smart ring maker Oura pulls IPO, 2026-09. This is an exclusive report. We could not verify the company’s original statement. ↩︎
Nasdaq daily historical quote API (XBI, with IBB, SPY, and individual stocks available in the same format), accessed 2026-10-10. Price returns (excluding dividends), rate sensitivity, and the tools basket returns are this analysis’s own calculations. ↩︎ ↩︎
Federal Reserve, FOMC statement, 2026-09-16. ↩︎
U.S. Treasury, Daily Treasury Par Yield Curve Rates 2026, value for 2026-10-09. ↩︎
IQVIA, Biopharma M&A mid-year 2026 update, 2026-07-08. This is a secondary aggregation and counts only transactions worth at least $250 million involving majority stakes. ↩︎ ↩︎
BioBucks, Biotech IPO Tracker 2026, updated 2026-10-09. This is a secondary aggregation, and its deal count differs from other trackers. ↩︎
FDA, Novel Drug Approvals for 2026, as of 2026-10-09. It includes approvals by the Center for Drug Evaluation and Research (CDER) only. ↩︎ ↩︎
Thermo Fisher, Q2 2026 earnings release (SEC 8-K), 2026-07-23. This analysis calculated tools company multiples from each company’s SEC filings. ↩︎ ↩︎
GRAIL, Q2 2026 earnings release (SEC 8-K), 2026-08-05. This analysis calculated multiples and revenue per test. ↩︎
GRAIL, FDA advisory committee results press release, 2026-09-23. ↩︎
FDA, Executive Summary for the Molecular and Clinical Genetics Panel, 2026-09-23. ↩︎
Freenome, S-1 registration statement, 2026-08-18. The $509 figure is the value the company reported from the legislation. ↩︎
Hinge Health, Q2 2026 earnings release (SEC 8-K), 2026-08-04. ↩︎
Omada Health, Q2 2026 earnings release (SEC 8-K), 2026-08-06. ↩︎
Oscar Health, Q2 2026 earnings release (SEC 8-K), 2026-08-06. ↩︎
10x Genomics, Q2 2026 earnings release (SEC 8-K), 2026-08-06. The explanation of delayed equipment purchases also appears in the earnings call transcript, a secondary source. ↩︎
Twist Bioscience, Q3 FY2026 earnings release (SEC 8-K), 2026-08-03. ↩︎
Twist Bioscience, 8-K (Anthropic-related filing), 2026-08-18. This translates only the filing language. It has not been confirmed whether the evaluator selection led to revenue. ↩︎
Danaher, Q2 2026 earnings release (SEC 8-K), 2026-07-21. ↩︎ ↩︎
Agilent, 10-Q (quarter ended July 31, 2026), accessed 2026-10-10. Percentage changes were calculated from the reported amounts. ↩︎
Goodwin, Final FY 2026 NDAA includes BIOSECURE, 2025-12. This is a law firm’s secondary analysis. We could not confirm whether the list had been announced as of Oct 10. ↩︎
Recursion, 10-Q (quarter ended June 30, 2026), accessed 2026-10-10. The runway figure is our own calculation and differs from the period stated by the company. ↩︎ ↩︎ ↩︎
Schrödinger, 10-Q (quarter ended June 30, 2026), accessed 2026-10-10. ↩︎
FDA, approval letter for lirafugratinib, 2026-09-23. ↩︎
Fierce Pharma, Elevar wins FDA nod for bile duct cancer drug Lyrfigtu, accessed 2026-10-10. This is secondary reporting. ↩︎
Relay Therapeutics, 10-Q (quarter ended June 30, 2026), accessed 2026-10-10. We have not confirmed the milestone amount tied to approval or when it will be received. ↩︎
Takeda, announcement of FDA acceptance for priority review of zasocitinib, 2026-09-14. ↩︎
BioPharm International, Isomorphic Labs raises $2.1 billion, accessed 2026-10-10. The funding took place in May 2026. This is secondary reporting. ↩︎
BioAge Labs, Q2 2026 earnings press release (SEC 8-K), accessed 2026-10-10. EV is our own calculation. ↩︎
Merck and Moderna, announcement of Phase 3 INTerpath-001 results, 2026-08-19. The one-day return was calculated using the Nasdaq closing price. ↩︎
United Therapeutics, Q2 2026 earnings press release (SEC 8-K), accessed 2026-10-10. ↩︎
Intellia, BLA acceptance and PDUFA announcement (SEC 8-K), accessed 2026-10-10. ↩︎
HLTH, Epic releases native AI Charting, 2026-02-06. ↩︎
Eli Lilly, 10-Q (quarter ended June 30, 2026), accessed 2026-10-10. ↩︎
BioBucks, Biotech M&A Tracker 2026, updated 2026-10-09. This is a secondary compilation. Premium benchmarks vary by transaction, and the median is our own calculation. ↩︎ ↩︎
Repligen, announcement of BioLife acquisition (2026-07-22) and closing press release (2026-10-06). The multiple is our own calculation based on trailing twelve-month revenue. ↩︎
Merck KGaA and Bio-Techne joint press release, 2026-06-25. The calculation divides the transaction enterprise value of $11.3 billion by FY 2026 revenue. ↩︎
Abbott, press release on completion of Exact Sciences acquisition, 2026-03-23. The multiple is our own calculation. ↩︎
Blackstone, announcement of Hologic acquisition terms. Closing was reported by 360Dx (2026-04-07, secondary source). ↩︎
Simulations Plus, press release on closing of acquisition, 2026-10-06. The multiple is our own calculation. ↩︎
SEC filing related to the Tempus-Personalis acquisition (Form 425), 2026-07. The multiple of 21.6x to 24.4x revenue is our own calculation based on 2025 revenue. ↩︎
Intuitive, Events and Presentations, accessed 2026-10-10. ↩︎
Thermo Fisher notice, Thermo Fisher Scientific to hold earnings conference call on October 21, 2026 (published on Finviz), 2026. ↩︎
Danaher notice, Danaher schedules third quarter 2026 earnings conference call (published on Finviz), 2026. ↩︎
Abbott announcement, Abbott hosts conference call for third-quarter earnings (published by Finviz), 2026. ↩︎
Quest Diagnostics, Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026, 2026. ↩︎
Moderna, announcement of late-breaking data presentation at ESMO 2026, accessed Oct 10, 2026. ↩︎
Insilico Medicine, Oral presentation at ESMO 2026 for phase 1 study of ISM6331, 2026. ↩︎
Hinge Health announcement, Hinge Health to announce third quarter 2026 financial results (published by StockTitan), 2026. ↩︎
Tecan, Investors, accessed Oct 10, 2026. ↩︎
Federal Register, final rule for the GLOBE model, Oct 2, 2026. Whether pharmaceutical industry lawsuits are underway is based on reporting (secondary source). ↩︎
OpenDART, Samsung Biologics disclosure of contract manufacturing agreement with European pharmaceutical company, Oct 2, 2026. $68.75 million (KRW 93.48 billion), through the end of 2031. ↩︎
OpenDART, ST Pharm disclosure of oligonucleotide raw material supply agreement with U.S. biotech company, Sep 18, 2026. $66.1 million (KRW 91.3 billion), 27.5% of recent revenue. ↩︎
OpenDART, ENCell disclosure of manufacturing supply agreement, Apr 20, 2026. The counterparty is a developer of advanced biopharmaceuticals, and the contract value is KRW 600 million. ↩︎
SmartToday, article on Seegene’s second-quarter results, accessed Oct 10, 2026. Regional shares are reported figures and were not cross-checked against the original half-year report. ↩︎
Medigate News, article on Seers Technology’s first-half results, accessed Oct 10, 2026. The approximately KRW 22 billion UAE supply figure is based on a News1 article; the actual order amount could not be confirmed. ↩︎ ↩︎ ↩︎
Dailypharm, article on Lunit’s first-half overseas revenue, accessed Oct 10, 2026. The overseas share is a reported figure. ↩︎
OpenDART, Noul disclosure amending its Panama supply contract, May 15, 2026. Payment dates were changed to June 30, September 30, and December 20. ↩︎ ↩︎
OpenDART, Curiosis disclosure of ODM supply agreement with Revvity, Jan 23, 2026. Three-year contract using a minimum order quantity (MOQ) structure. ↩︎
OpenDART, IBEAM Technology supply agreement disclosures for the NIEHS end customer ($428,900) and the Yale University end customer ($363,600), Sep 28, 2026. The scheduled installation and inspection date for the Yale order is Nov 30, 2026. ↩︎ ↩︎
BizWatch, article on IBEAM Technology’s U.S. orders and first-half exports, Sep 30, 2026. The export share is a reported figure. ↩︎
OpenDART, Protina disclosure of clinical specimen analysis service agreement, Sep 17, 2025. The counterparty is undisclosed under a disclosure deferral, and the contract runs through 2028. ↩︎
Daum News, article on Excel Therapeutics’ supply agreement with Shanghai Cell Therapy Group, May 21, 2026. The PL BioScience agreement is based on a Korea Economic Daily article, Jul 13, 2026. The original disclosures for both could not be confirmed. ↩︎
OpenDART developer guide, financial statements and company overview APIs, accessed Oct 10, 2026. Listing status was determined by whether a ticker appears in the company overview. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
OpenDART, Microdigital disclosure amending its supply agreement with Shinkou Seiki, Jun 16, 2026. The supply to Serum Institute is based on an EToday article. ↩︎
Eugene Investment & Securities, report on CuriOx Biosystems, Aug 23, 2023. Revenue trends are based on a FinanceScope article. Customer count reflects company-reported figures. ↩︎
OpenDART, Curiosis disclosure amending public procurement contract, Mar 5, 2026. ↩︎
OpenDART, Syntekabio disclosure of colocation service agreement, Jul 9, 2026. The 36-month contract begins Nov 1, 2026. ↩︎ ↩︎
OpenDART, Syntekabio antibody optimization (Ab-ARS) contract disclosure, 2026-09-11. ↩︎
Deepnoid company report (research), 2025-02-04. Segment weights are research figures and were not cross-checked against the original filing. The KRW 7.5 billion contract is in the OpenDART amended disclosure, 2025-09-30. ↩︎
OpenDART, Voronoi 2026 half-year report, 2026-10-02. ↩︎
OpenDART, PharosiBio 2025 business report, 2026-03-19. ↩︎
Alpha Distill, Bioneer research, 2026-04-20. Revenue weights are research figures and were not cross-checked against the original filing. ↩︎
BizWatch, article on ST Pharm’s order backlog, 2026-09-22. The order backlog and commercialization share are reported figures. ↩︎
DailyPharm, article on Samsung Biologics’ public tender offer for polypeptides, accessed 2026-10-10. ↩︎ ↩︎
OpenDART, Samsung Biologics amended rights offering disclosure, 2026-10-01. The payment date was checked against both news reports and the filing schedule. ↩︎
OpenDART, Vuno amended rights offering disclosure, 2026-09-29. ↩︎
OpenDART, SD Biosensor 2025 business report, 2026-03-18. Net loss is the consolidated key account value in OpenDART; news reports stated KRW 521.4 billion. ↩︎
DailyPharm, article on GC Cell goodwill amortization, accessed 2026-10-10. The net loss amount is from the OpenDART financial statements. ↩︎
OpenDART, LabGenomics 2025 business report, 2026-03-23. ↩︎

Tech Leaders on Korea Invest Insights